A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb

Autologous CAR T-cell therapies supply chain: challenges and opportunities?

(2020) Maria M. Papathanasiou et al.   CANCER GENE THERAPY

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40

(2020) Jessica Wenthe et al.   CANCER GENE THERAPY

Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms

(2020) Rong En Tay et al.   CANCER GENE THERAPY

Safety of CAR T-Cell Therapy in Patients with B-Cell Lymphoma and Chronic Hepatitis B or C Virus Infection

(2019) Paolo Strati et al.   BLOOD

High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study

(2019) Mari Morita-Fujita et al.   Clinical Lymphoma Myeloma & Leukemia

Challenges in assessing solid tumor responses to immunotherapy

(2019) Louis F. Chai et al.   CANCER GENE THERAPY

Peripheral T-cell lymphoma: novel backbone

(2018) Julie M. Vose   BLOOD

Translating anti-CD19 CAR T-Cell therapy into clinical practice for relapsed/refractory diffuse large B-Cell lymphoma

(2018) Victor A. Chow et al.   BLOOD

CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma

(2018) Alfonso Quintás-Cardama   Oncotarget

The promise of CAR T-cell therapy in aggressive B-cell lymphoma

(2018) Ranjit Nair et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience

(2017) Xiao Han et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma

(2017) Jeremy S. Abramson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Pathogenesis of Peripheral T Cell Lymphoma

(2015) Mamiko Sakata-Yanagimoto et al.   Current Hematologic Malignancy Reports

Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels

(2014) C. Bossard et al.   BLOOD

How I treat the peripheral T-cell lymphomas

(2014) A. J. Moskowitz et al.   BLOOD

Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice

(2014) Y. Chu et al.   Cancer Immunology Research

CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features

(2013) B. Bisig et al.   HAEMATOLOGICA

Distribution of Lymphoid Neoplasms in China

(2012) Jian Sun et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

(2012) Barbara Pro et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Peripheral T-cell lymphoma

(2011) F. M. Foss et al.   BLOOD

Subtype distribution of lymphomas in Southwest China: Analysis of 6,382 cases using WHO classification in a single institution

(2011) Qun-Pei Yang et al.   Diagnostic Pathology

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

(2009) Andres Forero-Torres et al.   BRITISH JOURNAL OF HAEMATOLOGY